三友医疗发布股份回购报告，最高回购金额达1.8亿元

回购方案概述

上海三友医疗器械股份有限公司（688085）于2026年7月27日发布了关于以集中竞价交易方式回购股份的回购报告书。公司董事会及全体董事承诺公告内容真实、准确、完整。

• 回购资金总额：不低于人民币9,000万元（含），不超过人民币18,000万元（含）。
• 回购价格上限：每股18.90元（含），不高于回购决议前30个交易日公司股票交易均价的150%。
• 预计回购股份数量：476.19万股至952.38万股，约占公司总股本的1.30%至2.60%。
• 回购资金来源：公司自有资金及已取得贷款承诺的专项贷款。
• 回购股份用途：拟在未来用于员工持股计划及股权激励，若三年内未全部使用，将注销剩余股份。
• 回购期限：自董事会审议通过回购方案之日起6个月内。

回购方案细节

本次回购以增强投资者信心、维护投资者利益、激励员工积极性、促进公司健康稳定发展为目标。回购股份将全部用于员工持股计划或股权激励方案。如果三年内未全部授出，剩余股份将依法注销。公司已开设专用证券账户用于本次回购。

回购实施期间的特殊规定与风险提示

• 若公司股票价格持续高于18.90元/股，可能导致回购无法全部或按计划实施。
• 若公司因外部环境或经营等原因无法筹措足够资金，回购可能无法实施或仅部分实施。
• 若公司生产经营、财务状况发生重大变化，或有重大事项影响股价，董事会有权变更或终止回购方案。
• 如股权激励或员工持股计划未能通过公司相关决策机构审议，或激励对象放弃认购，存在已回购股份无法全部授出的风险，剩余股份将被注销。
• 如遇监管政策变动，回购条款将按新规调整。

股东、高管及实际控制人动向及承诺

• 公司实际控制人及主要董事、高级管理人员、持股5%以上股东在未来3个月及6个月内均无减持计划。如有变动将及时披露。
• 回购决议前6个月，实际控制人及一致行动人有过股份减持（详见公告），但声明不存在内幕交易及市场操纵行为。
• 回购期间，实际控制人暂无增减持计划，其他董事、高管亦无明确增减持计划。

对公司经营及财务影响

• 以2026年3月31日数据测算，本次回购最大金额占公司总资产的7.65%、归属于母公司股东净资产的8.49%、流动资产的15.78%。公司有能力支付回购款项，不影响正常经营、研发和未来发展。
• 本次回购不会导致公司控制权变更，亦不会影响公司上市地位。

后续安排及信息披露

• 公司将在回购期限内根据市场情况择机实施回购，并及时披露进展。
• 如发生股份注销，公司将依法履行通知债权人等相关法定程序，保障债权人权益。
• 董事会已授权管理层具体办理回购相关事宜，包括设立专户、择机回购、应对政策变化、修改章程及工商变更等。

投资者须关注的重点与潜在影响

• 本次回购金额高达1.8亿元人民币，显示管理层对公司未来发展和二级市场价值的强烈信心。
• 回购股份主要用于员工激励，有助于提升公司治理和员工积极性，长期利好公司发展。
• 若回购未能在价格区间内顺利实施或遇到政策、资金等不确定性因素，可能对股价产生波动影响。
• 实际控制人、董事、高管在回购期间无减持计划，释放出稳定公司股价的积极信号。

结语

三友医疗本次大规模股份回购方案，无论从金额、用途还是管理层承诺来看，均具有较强的积极信号，或将对公司股价和市场信心产生正面推动作用。投资者应密切关注公司后续回购进展及相关公告，注意回购方案实施过程中的不确定性风险。

免责声明：
本文内容仅供信息参考，不构成任何投资建议或邀约。投资者须结合自身风险承受能力谨慎决策。公司后续可能因市场、政策等变化调整回购计划，敬请关注公司公告及市场动态。

English Version

Sanyou Medical Announces Share Buyback Plan up to RMB 180 Million

Overview of Buyback Plan

Shanghai Sanyou Medical Co., Ltd. (688085) on July 27, 2026, released its buyback report for purchasing shares via centralized bidding. The Board of Directors guarantees the truthfulness, accuracy, and completeness of the announcement.

• Total buyback amount: Not less than RMB 90 million (inclusive), not more than RMB 180 million (inclusive).
• Buyback price cap: RMB 18.90 per share (inclusive), no higher than 150% of the average trading price over the 30 days prior to the Board resolution.
• Expected number of shares to be repurchased: 4.7619 million to 9.5238 million shares, accounting for about 1.30% to 2.60% of total share capital.
• Source of funds: Company’s own funds and a dedicated buyback loan already committed by a bank.
• Purpose: All repurchased shares will be used for employee stock ownership plans or equity incentive schemes. Any shares not granted within three years will be canceled.
• Buyback period: Within 6 months from the date the Board approves the plan.

Detailed Plan

The buyback is aimed at enhancing investor confidence, protecting shareholder interests, motivating employees, and promoting stable long-term development. All repurchased shares will be used for employee incentives or equity plans. If not granted within three years, the remaining shares will be canceled. The company has set up a special securities account for this buyback.

Special Provisions and Risk Warnings

• If the share price remains above RMB 18.90 during the buyback period, the plan may not be fully executed as scheduled.
• If the company cannot raise the required funds due to external or operational factors, the buyback may only be partially implemented.
• If there are significant changes in operations, finances, or other factors, the Board may change or terminate the buyback.
• If incentive or ESOP plans fail to pass internal approvals, or recipients decline, there is a risk that not all repurchased shares will be granted. Unallocated shares will be canceled.
• If regulatory policies change, the buyback terms will be adjusted accordingly.

Shareholder, Executive and Insider Movements and Promises

• Controlling shareholders, directors, senior execs and 5%+ holders have no reduction plans in the next 3 or 6 months. Any changes will be disclosed in a timely manner.
• In the 6 months before the buyback resolution, some controlling shareholders and concerted actors reduced holdings (see announcement), but declare no insider trading or market manipulation.
• During the buyback, controlling shareholders have no plans to increase or decrease holdings, nor do directors or senior execs.

Impact on Operations and Financials

• Based on March 31, 2026 data, the maximum buyback amount will account for 7.65% of total assets, 8.49% of shareholders’ equity, and 15.78% of current assets. The company can afford the buyback with no material impact on operations, R&D, or future growth.
• The buyback will not result in a change of control or affect the company’s listing status.

Subsequent Steps and Disclosure

• The company will implement the buyback in stages as market conditions allow and will disclose progress in a timely way.
• If shares are canceled, the company will follow legal procedures to notify creditors and protect their rights.
• The Board authorizes management to handle all matters related to the buyback, including account setup, timing, price, responding to policy changes, amending articles of association, and business registration if needed.

Key Points and Potential Share Price Impact

• This large-scale buyback (up to RMB 180 million) signals strong management confidence in the company’s future and market value.
• Shares are for employee incentives, improving governance and motivation, a long-term positive for the company.
• If the buyback cannot proceed as planned due to price or policy, there may be some share price volatility.
• Controlling shareholders, directors, and execs have no reduction plans during the buyback, signaling stability and support for the share price.

Conclusion

Sanyou Medical’s substantial share buyback reflects strong confidence and a positive outlook. Investors should watch for further announcements and be aware of potential uncertainties during execution.

Disclaimer:
This article is for informational purposes only and does not constitute investment advice or an offer. Investors should make decisions based on their own circumstances and risk tolerance. The company may adjust its buyback plan due to market or policy changes; please pay attention to official disclosures and market dynamics.

View 三友医疗 Historical chart here